John Kane III, MD, Chief of the Melanoma/Sarcoma Service, and Joseph Skitzki, MD, Assistant Professor of Surgical Oncology and Associate Member of the Department of Immunology, discuss a specialized cancer therapy known as HIPEC Cytoreduction/Hyperthermic Intraperitoneal Chemoperfusion. This complex procedure, in use at RPCI for a decade, involves direct application of chemotherapy agents to abdominal cancers. HIPEC is primarily used to treat appendiceal tumors, but can also be an effective therapy for some colorectal or mesothelioma tumors. Drs. Kane and Skitzki describe HIPEC and explain which patients are most likely to be good candidates for the procedure.